PCSA Stock Forecast: Processa Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.56
−7.69% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 21 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$4.7M
Ticker Nerd rank
21/ 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$2.3M
Net income−$3.3M
Free cash flow−$2.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−16.1%
1M
−12.8%
YTD
−45.8%
1Y
−77.1%
From 52W high
−79.5%
From 52W low
+15.6%
$1.35
$7.63
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Processa Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
21/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
59
Volatility
52
Value
52
Quality
38
Issuance
26
Revisions
20
Growth
13
Momentum
7

Accruals (59): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PCSA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PCSA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00$7.00Jan 26Apr 26Jul 26Oct 26PCSA

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first

Of the 19 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
2 Sept 2025HC Wainwright & Co.MaintainsBuy$2.00 → $1.00
30 June 2025HC Wainwright & Co.MaintainsBuy—
5 Dec 2024HC Wainwright & Co.ReiteratesBuy—
3 Oct 2024HC Wainwright & Co.ReiteratesBuy$6.00
20 Aug 2024HC Wainwright & Co.ReiteratesBuy—
19 Aug 2024HC Wainwright & Co.MaintainsBuy—
1 Aug 2024HC Wainwright & Co.ReiteratesBuy—
12 June 2024HC Wainwright & Co.ReiteratesBuy—
13 May 2024HC Wainwright & Co.ReiteratesBuy—
25 Apr 2024HC Wainwright & Co.InitiatesBuy—
6 Mar 2024BenchmarkReiteratesSpeculative Buy—
17 Nov 2023Maxim GroupDowngradeHold—
4 Apr 2023BenchmarkMaintainsSpeculative Buy$9.00 → $4.00
3 Apr 2023OppenheimerMaintainsOutperform$5.00 → $3.00
12 Jan 2023Maxim GroupMaintainsBuy$9.00 → $5.00
19 Apr 2022Maxim GroupInitiatesBuy$9.00
3 Aug 2021OppenheimerInitiatesOutperform—
2 Aug 2021OppenheimerInitiatesOutperform—
28 Oct 2020Craig-HallumInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

PCSA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PCSA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Processa Pharmaceuticals, Inc. returned −77.1% against +6.9% for the S&P 500, dividends included.

PCSA vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26PCSAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PCSA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−10.2%

Higher than 26% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Processa Pharmaceuticals, Inc. has a market value of $4.7M and an enterprise value of $186.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$13.4M.

  • Free cash flow in the twelve months to 30 June 2026: −$13.3M.

  • Processa Pharmaceuticals, Inc. spent $320.0 on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 2.8M.

  • Processa Pharmaceuticals, Inc. employs 12 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

PCSA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PCSAProcessa Pharmaceuticals, Inc.$4.7M21
AIMAIM ImmunoTech, Inc.$4.5M33
SNTISenti Biosciences Holdings, Inc.$4.6M33
PULMPulmatrix, Inc.$4.6M47
CRISCuris, Inc.$4.1M35
CDIOCardio Diagnostics Holdings, Inc.$4.7M20
LTRNLantern Pharma, Inc.$3.9M24

Take a look at PCSA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Processa Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about PCSA

How does Ticker Nerd's model rank PCSA?

As at 21 Nov 2026, Processa Pharmaceuticals, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (59 of 100).

What is the PCSA stock forecast for 2030?

No analyst covering Processa Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PCSA are extrapolating price history, which says nothing about the business.

How has PCSA stock performed over the past year?

Processa Pharmaceuticals, Inc. returned -77.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Processa Pharmaceuticals, Inc. do?

Processa Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation chemotherapy and other therapies for serious diseases with high unmet medical needs. The company’s current portfolio centers on oncology programs designed to improve the safety and efficacy of existing cancer treatments by modifying how approved drugs are metabolized and distributed while preserving their cancer-killing mechanisms.

Company

About Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation chemotherapy and other therapies for serious diseases with high unmet medical needs. The company’s current portfolio centers on oncology programs designed to improve the safety and efficacy of existing cancer treatments by modifying how approved drugs are metabolized and distributed while preserving their cancer-killing mechanisms. Its pipeline also includes non-oncology candidates for conditions such as gastroparesis and glomerular disease. Processa Pharmaceuticals uses a regulatory science-driven approach to advance drug candidates that aim to offer better treatment options for patients facing complex medical conditions. Headquartered in Vero Beach, Florida, Processa Pharmaceuticals participates in the broader pharmaceutical innovation market through research, clinical development, and product pipeline advancement.

CEO Mr. George K. Ng Esq., J.D. · 12 employees · United States · https://www.processapharmaceuticals.com